Breaking Boundaries: Atavistik Bio and Pfizer Join Forces to Revolutionize Precision Allosteric Therapeutics
Description:
Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets. Atavistik Bio has rapidly identified novel, functional, allosteric binding pockets across a broad range of intractable target classes.
Collaboration with Pfizer will enable Atavistik Bio to extend the reach of its platform to potentially address a broader range of oncology indications, while simultaneously progressing its internal pipeline of precision oncology small molecule therapies.
CAMBRIDGE, Mass., Jan. 02, 2025 (GLOBE NEWSWIRE) — Atavistik Bio, a biotechnology company committed to discovering the next generation of precision allosteric therapeutics inspired by the body’s natural regulators, today announced that it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant unmet medical needs.
Blog Post Article:
In a groundbreaking move that is set to revolutionize the field of precision allosteric therapeutics, Atavistik Bio and Pfizer have announced a collaboration that will combine their expertise and resources to drive innovation and bring about much-needed advancements in the treatment of various medical conditions.
Atavistik Bio’s cutting-edge AMPS™ platform will play a pivotal role in this collaboration, providing a powerful tool for the rapid identification and validation of novel allosteric binders against specific targets designated by Pfizer. With Atavistik Bio’s proven track record of uncovering functional allosteric binding pockets across a wide range of challenging target classes, this partnership holds immense promise for the development of groundbreaking therapies.
By joining forces with Pfizer, Atavistik Bio will not only be able to expand the reach of its platform to address a broader range of oncology indications but also advance its internal pipeline of precision oncology small molecule therapies. This collaboration represents a significant step forward in the quest to harness the body’s natural regulatory processes to create innovative treatments that could potentially transform the landscape of precision medicine.
The partnership between Atavistik Bio and Pfizer marks a significant milestone in the field of precision allosteric therapeutics, offering new hope for patients grappling with unmet medical needs. With both companies bringing their unique strengths and capabilities to the table, the possibilities for groundbreaking discoveries and transformative treatments are endless.
How it will affect me:
This collaboration could lead to the development of more effective and targeted treatments for a wide range of medical conditions, potentially offering new hope for individuals facing challenging health issues. As a patient, this partnership between Atavistik Bio and Pfizer holds the promise of innovative therapies that could significantly improve treatment outcomes and quality of life.
How it will affect the world:
The collaboration between Atavistik Bio and Pfizer has the potential to have a far-reaching impact on the field of precision medicine, paving the way for the development of novel therapies that could benefit patients worldwide. By combining their expertise and resources, these two companies are poised to drive innovation and bring about transformative changes in healthcare that could benefit society as a whole.
Conclusion:
In conclusion, the collaboration between Atavistik Bio and Pfizer represents a powerful union of innovation and expertise that has the potential to revolutionize the field of precision allosteric therapeutics. By leveraging their strengths and resources, these two companies are poised to make significant strides in the development of novel treatments that could address unmet medical needs and improve patient outcomes. This partnership marks an exciting chapter in the journey towards advanced precision medicine, offering new hope for patients and the global healthcare community alike.
